SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

Rhea-AI Summary

SCYNEXIS, Inc. (NASDAQ: SCYX) announced a conference call and webcast scheduled for May 12, 2022, at 8:30 a.m. ET, to discuss its first-quarter financial results for the period ended March 31, 2022. The live audio webcast will be accessible via SCYNEXIS's Investor Relations page, and a replay will be available for 90 days post-event. SCYNEXIS focuses on developing innovative antifungal therapies, with its lead product, ibrexafungerp, recently approved by the FDA and set for commercial launch in the U.S. under the brand name BREXAFEMME.

Positive

• FDA approval of ibrexafungerp enhances market position.
• Initiation of commercial launch for BREXAFEMME in the U.S.

Negative

• None.

JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, May 12, 2022 to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2022.

Conference call and webcast details:

Investors (domestic): (877) 704-4453
Investors (international): (201) 389-0920
Webcast:  https://viavid.webcasts.com/starthere.jsp?ei=1543196&tp_key=e943d8c4f4
Conference ID: 13729053

A live audio webcast can be accessed by visiting the Investor Relations section of the Company’s website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME^® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, investigation and development of ibrexafungerp for the prevention of recurrent Vulvovaginal Candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com. 

CONTACT: 

Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Brett Whelan
LifeSci Communications
Tel: (339) 368-0466
bwhelan@lifescicomms.com

FAQ

What is the date of SCYNEXIS's upcoming conference call?

The conference call is scheduled for May 12, 2022, at 8:30 a.m. ET.

What financial results will SCYNEXIS discuss in the conference call?

SCYNEXIS will discuss its first-quarter financial results for the period ending March 31, 2022.

What is SCYNEXIS's lead product?

SCYNEXIS's lead product is ibrexafungerp, recently approved by the FDA.

What is the brand name for ibrexafungerp?

The brand name for ibrexafungerp is BREXAFEMME.

How long will the replay of the conference call be available?

The replay of the conference call will be available for 90 days following the event.